Location History:
- Pamplona, ES (2006 - 2009)
- Navarra, ES (2010)
Company Filing History:
2 out of 17 
1 out of 4 
1 out of 1 Years Active: 2006-2010
Title: The Innovations of Francisco Borras Cuesta
Introduction
Francisco Borras Cuesta is an esteemed inventor based in Pamplona, Spain, with a notable portfolio of four patents. His work primarily focuses on the development of peptides targeting specific proteins involved in various diseases. The impact of his inventions extends to innovative treatments for conditions linked to excessive growth factor activity, highlighting the intersection of biotechnology and therapeutic applications.
Latest Patents
Among his latest patents, two significant innovations stand out. The first patent focuses on "Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)." These peptides are designed to inhibit the biological activity of TGF-β1 by directly binding to this cytokine, showcasing potential applications in treating diseases associated with deregulated TGF-β1 expression.
The second patent involves a "Method for the treatment of skin fibrosis and suitable compositions for such treatment." This method utilizes peptide P144, an established inhibitor of TGF-β1, to treat skin fibrosis via topical application. Remarkably, the method demonstrated effectiveness in an animal model of bleomycin-induced skin sclerosis, leading to reduced skin fibrosis and soluble collagen content, all while showing no systemic toxicity. This highlights P144's promise in addressing fibrotic skin diseases and pathological scarring, along with stable, user-friendly compositions for human administration.
Career Highlights
Throughout his career, Francisco has worked with reputable organizations focused on biomedical advancements, notably at Cima Biomedical Project and Digna Biotech. His contributions to the field are underscored by his innovative approach to peptide development, which addresses significant medical challenges.
Collaborations
Francisco has collaborated with esteemed colleagues, including Ignacio José Ezquerro Saenz and Juan José Lasarte Sagastibelza. Their collective efforts have furthered research in the capabilities of peptides and their potential therapeutic applications.
Conclusion
Francisco Borras Cuesta's contributions to the field of biotechnology and his advancements in peptide research reflect his commitment to innovation in medicine. With a strong patent portfolio, he continues to lead the way in developing effective treatments for diseases impacted by TGF-β1, thereby improving the lives of many patients.